Oral bexarotene in a therapy-resistant Sézary syndrome patient: Observations on Sézary cell compartmentalization

International Journal of Dermatology

Volumn 44, Issue 1, 2005, Pages 25-28

  El Azhary, Rokea A ^a   Bouwhuis, Saskia A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIINFECTIVE AGENT; BEXAROTENE; CHLORMETHINE; CLADRIBINE; CORTICOSTEROID; FENOFIBRATE; GEMFIBROZIL; METHOTREXATE; PSORALEN;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; CASE REPORT; CAUSE OF DEATH; CELL COMPARTMENTALIZATION; CELL COUNT; CLINICAL OBSERVATION; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; ERYTHRODERMA; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LYMPH NODE; MALE; MEDICAL DOCUMENTATION; MYALGIA; PERIPHERAL CIRCULATION; PRURITUS; PUVA; RECURRENT DISEASE; SEPSIS; SEZARY SYNDROME; STAPHYLOCOCCUS AUREUS; ULTRAVIOLET B RADIATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DERMATITIS, EXFOLIATIVE; ERYTHEMA; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; PRURITUS; RETINOID X RECEPTORS; SEZARY SYNDROME; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 13444266494     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02132.x     Document Type: Article

References (14)

1. Burg G, Haffner A, Boni R, et al. New perspectives in experimental and clinical research for cutaneous T cell lymphomas. Recent Results Cancer Res 1995; 139: 225-237.
2. Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol 1999; 26: 276-289.
3. Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology 1999; 199: 102-105.
4. Bunn PA Jr. Cutaneous T cell lymphomas. Br Med J 1994; 308: 551-552.
5. Boehm MF, Zhang L, Badea BA, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994; 37: 2930-2941.
6. Nagy L, Thomazy VA, Shipley GL, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995; 15: 3540-3551.
7. Rizvi NA, Marshall JL, Dahut W, et al. A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999; 5: 1658-1664.
8. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15: 790-795.
9. Duvic M, Hymes K, Heald P, et al. for Members of the Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19 2456-2471.
10. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 34: 1022-1029.
11. Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 1994; 5: 115-125.
12. Cheng SX, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 649-652.
13. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-593.
14. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340: 1075-1079.